STAT October 21, 2024
Ed Silverman

The company says it wants to correct ‘inaccuracies’ as some urge the FTC to block the deal

Catalent, a leading contract drug manufacturer, issued an open letter on Monday to reassure customers that a proposed $16.5 billion deal — in which it would be acquired by Novo Nordisk’s parent — will not raise competitive concerns or diminish its ability to provide services to other drug companies.

...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
340B purchases hit $66.3B in 2023
Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer
Will Pharma Increase Use of Personalized Audio Use in Marketing?
Inside the financial struggles at CVS, Walgreens
Pharmaceutical research on mRNA and CAR T-cell therapy in cancer: Pioneering the future of oncology

Share This Article